- Conditions
- Mantle Cell Lymphoma
- Interventions
- Bendamustine, Rituximab, Cytarabine, Pegfilgrastim, Leukapheresis, Filgrastim, Autologous stem cell transplant
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1489–1512
of 3,574
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Childhood Langerhans Cell Histiocytosis, Fanconi Anemia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, melphalan, methylprednisolone, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Lymphoma, Leukemia
- Interventions
- Zevalin Radioimmunotherapy, Rituximab, Fludarabine, Cyclophosphamide, Allogeneic Stem Cell Transplantation
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
- Interventions
- bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, dexamethasone, filgrastim, pegfilgrastim, Autologous stem cell transplantation (ASCT)
- Drug · Biological · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lymphoma, Follicular
- Interventions
- HuMax-CD20
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Lymphoma, Nonneoplastic Condition
- Interventions
- polymerase chain reaction, laboratory biomarker analysis
- Genetic · Other
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 16
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 11 more
- Conditions
- Solid Tumor, Lymphoma
- Interventions
- Ad-p53
- Drug
- Lead sponsor
- MultiVir, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Morristown, New Jersey
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- intravenous T900607-sodium
- Drug
- Lead sponsor
- Tularik
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 5
- States / cities
- La Jolla, California • Aurora, Colorado • Chicago, Illinois + 1 more
- Conditions
- Primary Central Nervous System Non-Hodgkin Lymphoma
- Interventions
- rituximab, yttrium Y 90 ibritumomab tiuxetan
- Biological · Radiation
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
- Interventions
- Zanubrutinib, Obinutuzumab
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Las Vegas, Nevada + 1 more
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- ibritumomab tiuxetan, BEAM chemotherapy and autologous stem-cell transplantation
- Drug · Procedure
- Lead sponsor
- Sheba Medical Center
- Government
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 3 more
- Conditions
- Lymphoma, B-cell Lymphoma, Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Interventions
- Fludarabine, Cyclophosphamide, Total body irradiation, Tacrolimus, Mycophenolate Mofetil, Rituximab, Allogeneic Bone Marrow Transplant (BMT)
- Drug · Radiation · Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 1 Year to 75 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Neoplasms, Solid Tumor, Adult, Non-Hodgkin Lymphoma, Myelodysplastic Syndromes
- Interventions
- JNJ-64619178
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 4
- States / cities
- Sarasota, Florida • Boston, Massachusetts • Columbus, Ohio + 1 more
- Conditions
- Mild Cognitive Impairment, Cognitive Decline, Cognitive Deterioration, Cognitive Deficits, Mild, Cognitive Impairment, Mild
- Interventions
- Brain Health Academy, Brain Health Together, Maintain Brain Health Together
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Lymphoma, Large-Cell, Ki-1, Lymphoma, T-Cell
- Interventions
- UCN-01 (7-hydroxystaurosporine)
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- IDEC-114
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Rochester, Minnesota • Buffalo, New York + 1 more
- Conditions
- B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
- Interventions
- Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat, Pharmacokinetic Study, Pharmacological Study
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Duarte, California • Buffalo, New York
- Conditions
- T-Cell Acute Lymphoblastic Leukemia/Lymphoma
- Interventions
- Allogeneic anti-CD7 CAR-T cells (BEAM-201)
- Biological
- Lead sponsor
- Stephan Grupp MD PhD
- Other
- Eligibility
- 0 Years to 29 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Mild and Moderate Hepatic Impairment
- Interventions
- MT-7117
- Drug
- Lead sponsor
- Tanabe Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Solid Tumor, Lymphoma, Peripheral T-Cell Lymphoma
- Interventions
- ALRN-6924
- Drug
- Lead sponsor
- Aileron Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Duarte, California • Denver, Colorado + 9 more
- Conditions
- Mycosis Fungoides
- Interventions
- mechlorethamine-MCH (nitrogen mustard)
- Drug
- Lead sponsor
- Yaupon Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 12
- States / cities
- Stanford, California • Chicago, Illinois • New York, New York + 7 more
- Conditions
- Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma
- Interventions
- Zevalin, Y-90-Zevalin, Rituximab, In-111 Zevalin
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 28
- States / cities
- Casa Grande, Arizona • Berkeley, California • Duarte, California + 24 more
- Conditions
- Lymphoma
- Interventions
- ifosfamide, paclitaxel, teniposide, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hemorrhoid
- Interventions
- Hemorrhoidopexy
- Device
- Lead sponsor
- Medtronic - MITG
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York